Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

BACKGROUND: We sought to ascertain the immune effector function of pembrolizumab within the glioblastoma (GBM) microenvironment during the therapeutic window. METHODS: In an open-label, single-center, single-arm phase II “window-of-opportunity” trial in 15 patients with recurrent (operable) GBM rece...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: de Groot, John, Penas-Prado, Marta, Alfaro-Munoz, Kristin, Hunter, Kathy, Pei, Be Lian, O’Brien, Barbara, Weathers, Shiao-Pei, Loghin, Monica, Kamiya Matsouka, Carlos, Yung, W K Alfred, Mandel, Jacob, Wu, Jimin, Yuan, Ying, Zhou, Shouhao, Fuller, Gregory N, Huse, Jason, Rao, Ganesh, Weinberg, Jeffrey S, Prabhu, Sujit S, McCutcheon, Ian E, Lang, Frederick F, Ferguson, Sherise D, Sawaya, Raymond, Colen, Rivka, Yadav, Shalini S, Blando, Jorge, Vence, Luis, Allison, James, Sharma, Padmanee, Heimberger, Amy B
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7158647/
https://ncbi.nlm.nih.gov/pubmed/31755915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz185
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados